NEW YORK (CNN/Money) - Drug and consumer products manufacturer Johnson & Johnson posted higher third-quarter earnings and revenue Tuesday that topped forecasts on Wall Street.

YOUR E-MAIL ALERTS Johnson & Johnson Incorporated Pharmaceuticals Stock Exchanges Consumer Goods or Create your own Manage alerts | What is this?

The maker of Band-Aids, Tylenol and a host of prescription drugs earned $2.3 billion, or 78 cents share, up from $2.1 billion, or 69 cents, a year earlier. Analysts surveyed by earnings tracker First Call forecast 76 cents.

Revenue rose 10.5 percent to $11.6 billion. The company said that it saw a 7.7 percent growth in sales, and revenue increased 2.8 percent due to the effect of changes in currency-exchange rates. First Call's forecast called for revenue to rise to $11.3 billion in the period.

The company saw broad-based revenue gains across its various business lines. Revenue from consumer products gained nearly 10 percent to $2 billion, while prescription drug revenue rose 13.4 percent to $5.5 billion.

Medical devices and equipment revenue increased 7 percent to $4 billion as a decline in domestic sales was overcome by a 12.8 percent increase in overseas sales before the gains from currency-exchange rates.

Shares of Johnson & Johnson (JNJ: Research, Estimates), a component of the Dow Jones industrial average, gained 4 cents to $55.36 in trading Monday ahead of Tuesday's report.